Genetic Systems technology purchase
Firm purchased from Cutter all rights to its Phase/research program for the production of therapeutic human monocional antibodies for hospital-acquired infections from gram negative bacteria. Two firms had previously agreed to undertake the research in October 1983. Under a separate agreement with the Cutter Group, Genetic Systems is developing human monoclonal antibodies to pseudomonas bacteria. Antibodies have bean transferred to Cutter for scale-up and clinical trials. Genetic Systems said it will receive a royalty on all saies of products for pseudomonas infections.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.